Trials / Conditions / Light Chain Deposition Disease

Light Chain Deposition Disease

10 registered clinical trials studyying Light Chain Deposition Disease — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH NCT05283993	Peking University First Hospital	—
Active Not Recruiting	Rifaximin in Patients With Monoclonal Gammopathy NCT03820817	Emory University	Phase 1
Recruiting	Registry for Adults With Plasma Cell Disorders (PCD's) NCT03717844	UNC Lineberger Comprehensive Cancer Center	—
Completed	Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Mye NCT01849783	Margarida Magalhaes-Silverman	Phase 2
Terminated	First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD NCT01728259	Barbara Ann Karmanos Cancer Institute	Phase 1
Completed	Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT01533194	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma NCT01169337	National Cancer Institute (NCI)	Phase 3
Completed	Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic NCT01078454	National Cancer Institute (NCI)	Phase 3
Completed	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747	National Cancer Institute (NCI)	Phase 1
Completed	Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Depositi NCT00520767	Barbara Ann Karmanos Cancer Institute	Phase 2